Would you consider using ensartinib in patients with ALK-positive NSCLC who have progressed on alectinib and lorlatinib?

Will you continue targeted therapy with ensartinib in patients with ALK+ metastatic NSCLC after alectinib and lorlatinib failure?

• Yes, would trial ensartinib in these patients as next line of therapy
• Yes, would trial ensartinib in these patients but only after 1+ lines of cytotoxic chemotherapy between
• No, would not continue ALK targeting therapy in these patients
• No, but plan to use ensartinib over lorlatinib in patients with resistance mutations
• No, but plan to use ensartinib as my preferred frontline ALK TKI
• Other